Abstract: This study used high-performance liquid chromatography to measure 202 teicoplanin plasma trough concentrations (C min ) in 114 haematological malignancy patients with febrile neutropenia. Patients were divided into two groups according to the mean initial dose (MID) over the first 3 days of treatment: (i) MID = 533.33 mg/day (loading dose group, 400 mg q12h for three doses followed by 400 mg qd, n = 62) and (ii) MID < 533.33 mg/day (unloaded or underloaded group, n = 52). During the first 3 days after treatment, the overall C min was higher in group 1 than in group 2 (10.96 AE 5.44 mg/L versus 6.31 AE 3.73 mg/L, mean AE S.D.; p = 0.002), as was the qualifying rate of C min > 10 mg/L (54.5% versus 11.1%, p = 0.001), and the probability of C min < 5 mg/L was lower in group 1 than in group 2 (13.6% versus 40.7%, p = 0.037). After 3 days, the average C min and qualifying rates did not differ significantly between the two groups, and the average C min was <10 mg/L in both groups. Binary logistic regression analysis revealed that creatinine clearance (p = 0.004) and MID (p = 0.010) could affect C min during the first 3 days of treatment and that age (p = 0.022) only could affect C min after 3 days. In conclusion, it is necessary to apply loading dose to achieve teicoplanin C min > 10 mg/L rapidly and, from a pharmacokinetic/pharmacodynamic perspective, 600 mg is recommended as loading and maintenance dose for these patients when AUC 24 /minimum inhibitory concentration > 345.
Haematological malignancy patients with febrile neutropenia constitute a population with special diseases. Because the associated pathogens and their foci are unclear, fever may be the only sign of infection [1] . The multi-centre prospective epidemiological study of Yan [2] involving patients with haematological diseases in China found that the most common pathogenic bacteria were Gram-negative bacteria (44.5%), followed by Gram-positive bacteria (38.0%) and fungi (17.5%) . The data of the Chinese bacterial resistance monitoring network showed that the average detection rates of methicillin-resistant Staphylococcus aureus (MRSA) in 2015 and 2016 reached 42.2% and 38.4%, respectively [3, 4] . Therefore, in view of the current status of epidemiology in China, we should attach great importance to infection by Grampositive cocci (especially resistant bacteria) in the empirical anti-infectives of neutropenic patients with haematological malignancies [5] .
Some guidelines mention that the addition of glycopeptide antibacterials is recommended in patients with febrile neutropenia when there is severe mucositis or catheter-related infection [6] . Teicoplanin and vancomycin are glycopeptide antibacterials that inhibit bacterial cell-wall peptidoglycan synthesis and are the first-line treatment for drug-resistant Gram-positive bacteria [1] . Both of them are effective in febrile neutropenic patients [7] , and compared with vancomycin, teicoplanin has advantages of comparable antibacterial activity, post-antibiotic effect and lower frequency of nephrotoxicity or red-man syndrome [8, 9] , and so teicoplanin can be used as an initial empirical choice for febrile neutropenic patients with haematological malignancies [10] . Ziglam et al. [11] showed that teicoplanin was chosen approximately twice as often as vancomycin for the second-line antimicrobials when empirical therapy did not respond after 24-48 hr for febrile neutropenic patients in oncology units.
Teicoplanin is a time-dependent antibacterial with long elimination half-life, and its plasma trough concentration (C min ) is closely related to the clinical efficacy [7, [12] [13] [14] . Maintaining the C min of teicoplanin above 10 mg/L can effectively control general infections [15] . For febrile neutropenic patients with bacteraemia, the teicoplanin C min must be at least ≥15.2 mg/L [8] or 15-20 mg/L [7] . For endocarditis, septicaemia and bone or joint infections, the C min of teicoplanin should exceed 20 mg/ L in immunosuppressed patient [8, 16] . The current common dosage regimen first applies teicoplanin at 400 mg q12h for three doses as a loading dosage, followed by 400 mg qd as a maintenance dosage in Chinese instructions, and teicoplanin C min higher than 10 mg/L is recommended.
Because haematological malignancy patients often exhibit an enhanced renal clearance [17, 18] or hypoalbuminaemia [19] , the pharmacokinetics of teicoplanin often changes.
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Several authors [20] [21] [22] have shown that renal clearance of hydrophilic antibacterials, including glycopeptide antibacterials, may be substantially enhanced in patients with haematological malignancies. So, the standard dosage regimens therefore often fail to achieve an adequate C min for those patients [23] . Optimizing the dosage regimen based on pharmacokinetic/pharmacodynamic (PK/PD) parameters may improve clinical outcomes in haematological malignancy patients with a high risk of infection [23] . This study suggests that teicoplanin achieves the best clinical outcome when the area under the serum concentration-time curve over 24 hr (AUC 24 ) divided by the minimum inhibitory concentration (MIC) is higher than 345 for severe infection [24] [25] [26] . The optimal teicoplanin dosage also differs for pathogens with different MIC: for a higher MIC, the dose should be increased or the administration interval should be shortened to increase the probability of achieving AUC 24 /MIC > 345.
Although many studies [7, 12, 14, 16, [27] [28] [29] [30] have considered that the standard dosage regimen of teicoplanin does not meet the desired C min for haematological malignancy patients with febrile neutropenia, they have not yet recommended suitable doses for this population. Therefore, this study tried to further investigate whether the current common loading dose of teicoplanin can achieve the desired C min of 10 mg/L rapidly and whether or not the common maintenance dose is appropriate, as well as the factors affecting the C min of teicoplanin in those patients. At last, we expect to optimize the teicoplanin dose for those patients by Monte Carlo simulations (MCS) from a PK/ PD perspective when AUC 24 /MIC > 345 is required.
Methods
Patients and data collection. This was a single-centre, retrospective study. We enrolled haematological malignancy patients who were hospitalized in the Department of Hematology, the First Affiliated Hospital of Xi'an Jiaotong University from November 2015 to August 2017. The following inclusion criteria were applied: age ≥18 years, diagnosed or suspected clinically with Gram-positive cocci infections and conformity with criterion of febrile neutropenia with reference to the Chinese guideline [1] . The exclusion criterion was dying within 24 hr after teicoplanin usage. There was no restriction on gender.
Neutropenia was defined as a peripheral blood absolute neutrophil count (ANC) below 0.5 9 10 9 /L or an estimated ANC below 0.5 9 10 9 /L after 48 hr. Fever was defined as single oral and armpit temperature measurements higher than 38.3°C and 38.0°C, respectively, or a single oral temperature measurement higher than 38.0°C and an armpit temperature above 37.7°C lasting for more than 1 hr. The treatment with teicoplanin was considered effective when the signs of fever and clinical infection had decreased by 72 hr. For patients who met the inclusion criteria, researchers collected data on gender, age, body-weight, clinical diagnosis, co-infection, teicoplanin regimen, serum creatinine, albumin and bacteriological culturing by referring to the medical records.
Sample collection and therapeutic drug monitoring. During the application of teicoplanin, at least one plasma sample of the teicoplanin C min was collected during the first 3 days and then after the first 3 days of teicoplanin treatment. Venous blood (2 mL) collected in the contralateral forearm of the vein infusion arm was placed in an anticoagulant tube with EDTA. The plasma sample obtained after centrifugation was placed in a deep freezer at À80°C until testing. The teicoplanin C min was measured using highperformance liquid chromatography [31] . This study was reviewed and approved by the ethics committee of the First Affiliated Hospital of Xi'an Jiaotong University [document number 2015(036)].
Grouping according to teicoplanin regimen. Patients were divided into two groups according to the mean initial dose (MID) over the first 3 days. MID was calculated as (dosing on day 1+ dosing on day 2+ dosing on day 3)/3 [32] . Group 1 received MID = 533.33 mg/day (loading dose group, 400 mg q12h for three doses followed by 400 mg qd, n = 62), while group 2 received MID < 533.33 mg/day (unloaded or underloaded group, n = 52). Teicoplanin was slowly injected in 3 mL of water into the ampoule and then gently shaken until the powder had completely dissolved. The liquid was then completely aspirated into the syringe and added to 250 mL of 0.9% sodium chloride injection for use. The infusion time was >60 min.
Monte Carlo simulations. The PK parameters of haematological malignancy patients with febrile neutropenia were expressed as lognormal distributions and quantified as mean AE S.D. values (0.86 AE 0.38 L/hr) [12, 28] . For MIC, a discrete distribution ranging from 0.004 to 64 mg/L based on reported data was analysed by MCS. The MCS were performed with 10,000 replicates using Crystal Ball software (version 11.1.1.1.00, Fusion Edition, Oracle) based on the following formula:
where AUC 24 is in mgÁhr/L, D is the daily administered teicoplanin dose (mg), s is the dosing interval (hr) and CL t is the total body clearance (L/hr).
An AUC 24 /MIC > 345 was the PK/PD target of teicoplanin, and the MCS was used to calculate the probability of reaching that target. The results of the MCS were expressed as the probability of target attainment (PTA) and the cumulative fraction of response (CFR) [33] . A PTA value of >90% and a CFR value of >90% were considered indicative of an appropriate dosage regimen.
Statistical analysis. The primary measured parameter was C min . The Kolmogorov-Smirnov test was used to assess whether the data conformed to a normal or a non-normal distribution. Accordingly, mean AE S.D. values or median and interquartile range (IQR) values were used for descriptive statistics. Binary logistic regression analysis was used to identify variables that were correlated with the teicoplanin C min . Binary logistic regression analysis and the chi-square test were conducted using SPSS software (IBM SPSS Statistics 19.0, Xi'an, China). A probability value of p < 0.05 was considered to indicate a statistically significant difference.
Results

Study population.
In total, 202 plasma samples from 114 patients were screened for teicoplanin C min monitoring. Twenty-one samples from 20 patients were not detected (13 samples from 12 patients in group 1 and eight samples from eight patients in group 2) due to these C min values being below the detection limit. Blood or sputum specimens of those patients were sent for aetiological culturing before teicoplanin was administered; however, all of the bacterial culture results were negative. Teicoplanin was therefore considered to be an empirical anti-infective treatment. The demographic data of the patients in this study are listed in table 1. None of the basic characteristics differed significantly between the two groups of patients. The dosage regimens of 52 patients in group 2 are presented in table 2. Figure 1 shows C min scatter plots for the 181 samples from 94 haematological malignancy patients with febrile neutropenia. The overall C min was 7.70 AE 4.87 mg/L, and only 27.1% of the samples (49/181) had a C min higher than 10 mg/L.
Teicoplanin plasma trough concentrations during the first 3 days after treatment. During the first 3 days, the C min values of 22 samples from 22 patients in group 1 and 31 samples from 31 patients in group 2 were monitored. Four samples from four patients in group 2 were not detected because they were below the detection limit. The overall C min was higher in group 1 than in group 2 (10.96 AE 5.44 mg/L versus 6.31 AE 3.73 mg/L, p = 0.002), as was the percentage of samples with C min > 10 mg/L [54.5% (12/22) versus 11.1% (3/27)] (p = 0.001). As can be seen from fig. 2A , the percentage of patients with C min < 5 mg/L was higher in group 2 than in group 1 [40.7% (11/27) versus 13.6% (3/22)] (p = 0.037).
Teicoplanin plasma trough concentrations after the first 3 days of treatment. After the first 3 days of treatment, the C min values of 104 samples from 53 patients in group 1 and 45 samples from 32 patients in group 2 were monitored. Among them, 13 samples from 12 patients in group 1 and four samples from four patients in group 2 were not detected because they were below the detection limit. The overall C min values in groups 1 and 2 were 7.03 AE 4.79 mg/L and 8.35 AE 4.66 mg/L (p = 0.142). The probability rates of C min > 10 mg/L were 20.9% (19/91) and 36.6% (15/41) (p = 0.056) in groups 1 and 2, respectively. There was no significant difference in the percentages of samples in groups 1 and 2 within different concentration ranges ( fig. 2B ).
Factors affecting the trough concentration of teicoplanin. Binary logistic regression analysis was used with an entry method that applied the following assignment rules for the independent variables. Teicoplanin C min > 10 mg/L was included as a dependent variable (yes = 1, no = 0), and the covariates included the patients' gender, age, weight, plasma albumin, serum creatinine and creatinine clearance, all of which were actual test values, and MID = 533.33 mg/day (yes = 1, no = 0). The threshold for inclusion in the regression equation was 0.05 and that for rejection was 0.10. Overall, age (p = 0.004) and creatinine clearance (p = 0.024) were significant risk factors influencing the teicoplanin C min (table 3) . However, the teicoplanin C min was not linearly correlated with either age (R 2 Linear = 0.001) or creatinine clearance (R 2 Linear = 0.007). During the first 3 days of treatment, C min was affected by creatinine clearance (p = 0.004) and MID (p = 0.010), and thereafter, it was affected by age (p = 0.022) only, with no statistical significance for plasma albumin (p = 0.053).
Evaluation of probability of target attainment and cumulative fraction of response. Figure 3 shows the probability of PK/PD target attainment by the MIC for teicoplanin studied at dosage regimens of 200 mg, 400 mg, 600 mg and 800 mg qd. The selected target for haematological malignancy patients with febrile neutropenia was AUC 24 /MIC > 345, and all of the tested teicoplanin dosage regimens achieved PTA values of >99% for MIC ≤ 0.25 mg/L. The PTA was demonstrated with 600 mg qd for MIC of 0.5 and 1 mg/L, with values of 100% and 99%, respectively. In addition, the PTA was 81% for an MIC of 2 mg/L for 800 mg qd only and <60% for all of the other dosage regimens (fig. 3) . Table 5 presents the assessed CFR for different teicoplanin dosage regimens evaluated based on AUC 24 /MIC > 345 in the treatment of haematological malignancy patients with febrile neutropenia. For Enterococcus faecalis only, an average CFR value higher than 90% (90.46%) was obtained with a dose of 400 mg qd. For enterococci and staphylococci, a dose of 600 mg qd was required to ensure CFR >90%.
Discussion
High-dose chemotherapy-induced mucosal injury and the extensive use of intravenous catheters mean that Gram-positive bacterial infections in patients with haematological malignancy should not be ignored. This conclusion is supported by the current detection rate of Gram-positive bacterial infections being close to 40% in China [2] . For these patients, the timely application of empirical anti-infective drugs and achieving an adequate plasma concentration as rapidly as possible can improve the efficacy and reduce mortality. This study found that the qualifying rate of C min > 10 mg/L was higher in group 1 (loading dose group) than in group 2 (unloaded or underloaded, 54.5% versus 11.1%, p = 0.001) during the first 3 days of empirical treatment of Gram-positive infections using teicoplanin for haematological malignancy patients with febrile neutropenia. That is, the use of an adequate loading dose will facilitate reaching a teicoplanin C min higher than 10 mg/L as rapidly as possible. This is similar to the retrospective study of Nah [27] , finding that during the first 3 days of teicoplanin treatment, the probability of C min > 10 mg/L in the group with MID = 533.33 mg/day was higher than that in the group with MID < 533.33 mg/day (66.7% versus 20%, p = 0.09). However, the present study found that only 54.4% (62/114) of the patients received the loading dose, suggesting that more patients should be given the loading dose to increase the compliance rate during the initial period of treatment.
In this study, the overall C min during the first 3 days of treatment was only 10.96 AE 5.44 mg/L in group 1, which is insufficient for sepsis induced by Staphylococcus aureus. Pea [12] studied 33 cases of acute leukaemia after chemotherapy in patients with febrile neutropenia. None of the patients in the standard dosage group (n = 11, same as group 1 in the present study) reached the recommended C min > 10 mg/L during the first 3 days, and only 45% achieved this recommended value after 5 days. In the high-dosage group (n = 22, 800 mg + 400 mg q12h on day 1, 600 mg + 400 mg q12h on day 2 and 400 mg q12h from day 3 onward), the average C min was 10 mg/L within 1 day and reached the recommended value within 2 days (with the exception of one patient). Long-term exposure to suboptimal dose concentrations of glycopeptide antibiotics for Staphylococcus aureus is a major risk factor for drug resistance [34] , potentially resulting in drug resistance and leading to treatment failure or even death. It is therefore necessary to administer a higher loading dose to achieve an effective therapeutic concentration as rapidly as possible.
The overall C min values after the first 3 days of treatment were 7.03 AE 4.79 mg/L and 8.35 AE 4.66 mg/L in groups 1 and 2, respectively (p = 0.142). These results show that the teicoplanin C min is low, either 400 mg or 200 mg qd, and so the PK/PD characteristics of teicoplanin should be considered when developing a maintenance dose program to improve the teicoplanin C min and the qualifying rate of C min > 10 mg/L.
Current clinical practice is generally believed that the unreasonable loading dose administered is the main factor affecting the teicoplanin C min [35] . However, the results of the present study suggest that the teicoplanin C min is also affected by age and creatinine clearance (table 3) in haematological malignancy patients with febrile neutropenia, although not in a linear manner. These results are similar to those of Pea [36] , who found that C min was affected by creatinine clearance with moderate to good inverse linear relationship. During the first 3 days, creatinine clearance (p = 0.004) and MID (p = 0.010) might be the factors influencing the C min of teicoplanin in these patients, with C min only being affected by age thereafter (p = 0.022). Interestingly, Pea et al. [36] found that during the first 3 days, the dosage of teicoplanin was the only factor influencing C min , with a positive correlation. On the fourth day, in addition to the dosage, creatinine clearance and age also began to influence C min , with a negative correlation. Of note, firstly, our study included various haematological malignancy patients, whereas Pea's studies considered only patients with acute leukaemia. Secondly, the dosage regimens applied in this study were irregular and diversified, whereas those in Pea's studies were uniform, relatively. And thirdly, creatinine clearance calculated by Cockroft & Gault formula, which included age, may cause confounding factors between age and creatinine clearance. These may possibly explain the differences with our findings, for example the different influencing factors and the relationship between C min and creatinine clearance. Due to the higher creatinine clearance in patients with haematological malignancy, which were >140 mL/min. in both groups, the renal clearance of hydrophilic antibacterials may be enhanced substantially. Pea et al. [12] and Lortholary et al. [28] pointed out the necessity of higher teicoplanin dosage for those patients with higher creatinine clearance. On the other hand, the present study involved empirical anti-infective treatment, but the MIC values of potential pathogens need to be considered during treatment. A total of 86 and 28 patients were given maintenance doses of 400 mg and 200 mg qd, respectively. With a teicoplanin PK/PD target of AUC 24 / MIC > 345, the PTA was above 99% for 400 mg qd with an MIC of 0.5 mg/L, and it decreased to 81% for an MIC of 1 mg/L. That is to say, 600 mg of teicoplanin should be administered to maintain PTA higher than 90% for an MIC of 1 mg/L ( fig. 3) . Similarly, 600 mg of teicoplanin should be administered to maintain CFR above 90% for these target pathogens (table 5) . Many authors have proposed that highdose regimen in the first 3 days can achieve a higher C min [12, 29, 30, [37] [38] [39] . Gimenez et al. [40] and Pea et al. [12] suggested that higher loading doses of teicoplanin in neutropenic patients should be administered. So, we recommend a loading dose of 600 mg q12h for three doses during the first 3 days after treatment and a maintenance dose of 600mg once daily to reach the desired C min quickly from a PK/PD perspective when AUC 24 /MIC > 345 is required.
The limitations of this study are that it had a single-centre design, the dosage regimens were irregular and diversified, and the heterogeneity of the enrolled haematological malignancy patients in our study, which may be partly responsible for the large fluctuations in C min values, might represent a confounding factor and explain some of the differences. However, this also reflects the current situation in China, where there is no unified drug regimen for the empirical treatment of Gram-positive bacterial infections in patients with haematological malignancy, and hence, this needs to be regulated further.
In summary, this study shows that the empirical use of a teicoplanin regimen of 400 mg q12h for three doses as a loading dose in haematological malignancy patients with febrile neutropenia may result in some of these patients reaching C min > 10 mg/L rapidly; however, this needs to be increased to improve the qualifying rate. The findings of this study further suggest that this loading dose is not sufficient to achieve the effective concentration for haematological malignancy patients with sepsis caused by Staphylococcus aureus. If it is found to be necessary, the dosage regimen of 600 mg should be applied and loading dose is necessary in those patients, and the teicoplanin C min then needs to be monitored. Based on the present findings, we plan to further explore the PK of teicoplanin in patients of different ages. 
